Better care for epidemics
Regina getting into PPE before going into the red zone (Sierra Leone, Port Loko , 2015 – Ebola treatment centre – GOAL). Photo credit: Rebecca Inglis
International Severe Acute Respiratory and emerging Infection Consortium
What we do
Our purpose is to prevent illness and deaths from infectious disease outbreaks.
We are a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases.
In December 2019, a novel coronavirus (SARS-CoV-2) emerged to cause a pandemic of a severe coronavirus disease (COVID-19). ISARIC has created tools for investigators to collect and store data in a standardised way and has supported clinical trials of treatments.
ISARIC provides a collaborative platform through which global, patient‐oriented clinical studies can be developed, executed and shared.
Protocols addressing the most important questions between and during epidemics of severe acute respiratory infections and other rapidly emerging public health threats are undertaken in order to generate new knowledge, maximise the availability of clinical information, and thereby save lives.
Healthcare professionals in COVID-19 hospital (Photo credit: Professor Bin Cao, China-Japan Friendship Hospital, China)
In consultation with colleagues at WHO, the following
protocols and data tools were made available:
In January 2020, ISARIC launched an international initiative for standardised COVID-19 clinical data collection. Over the past nine months, there has been extensive global participation, resulting in one of the world’s largest collections of comprehensive clinical data for COVID-19.
ISARIC, based at Oxford University, in collaboration with Dr Janet Scott, of the MRC-University of Glasgow’s Centre for Virus Research, has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19.
The international, multi-site study is launched by ISARIC to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study.
ISARIC partners have been at the forefront of clinical trials of COVID-19 treatments since the start of the pandemic. Recognising how hard it is to keep up with the extraordinary pace of COVID science, ISARIC will run a series of ‘Evidence Fora’ on COVID-19 treatment.
Currently very little is known about the clinical, biological, psychological and socio-environmental impact of Coronavirus Disease 2019 (COVID-19). While most people have uncomplicated recoveries, some continue to live with prolonged illness and symptoms.